Dexamethasone can be used to treat non-infectious uveitis

Article

Ozurdex (dexamethasone) can now be used for the treatment of inflammation of the posterior segment of the eye characterized as non-infectious uveitis

Ozurdex (dexamethasone) can now be used for the treatment of inflammation of the posterior segment of the eye characterized as non-infectious uveitis, announced Allergan.

The drug is available in the majority of Europe as a licensed treatment for macular oedema in patients with retinal vein occlusion. The biodegradable implant gives an extended release of the anti-inflammatory corticosteroid dexamethasone by intravitreal injection, lasting for up to 6 months. The injection is administered with Allergan's NOVADUR solid polymer delivery system.

The safety and efficacy of Ozurdex was assessed in the HURON Phase III study. This was a randomized, multicentred, double-masked clinical investigation of 229 patients with non-infectious intermediate or posterior uveitis. Each patient was administered 0.35 mg or 0.7 mg of Ozurdex or sham injections.

The results of the study demonstrated a reduction in vitreous haze, an improvement in visual acuity and an overall improvement in vision functioning.

Mr Douglas Ingram, President of Allergan, Europe, Africa and the Middle East, said: “We are pleased with the Committee’s Positive Opinion today supporting the licensure of Ozurdex to treat non-infectious intermediate and posterior uveitis. This is a crucial step in the process to bring this innovative anti-inflammatory treatment option to physicians and their patients suffering from uveitis. This is also an important milestone for Allergan’s Retina franchise and demonstrates our continuing commitment to developing innovative new treatments that can help preserve vision for patients suffering from retinal diseases."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.